| Margins | EBITDA margin compressed to 3.24% in Q4 from 9.25% YoY. |
|---|---|
| Management confidence | High |
Growth
FY26 revenue down 5% YoY to ₹47.47cr; EBITDA down 13% to ₹3.63cr; PAT surged 325% to ₹2.20cr.
Outlook
Focus on building a stronger financial foundation through operational efficiency and higher quality of earnings.
Risks
Q4 revenue degrowth of 8% and significant EBITDA margin contraction from 9.25% to 3.24% YoY.
Source
Read the document ↗
Earnings Call filed with BSE, NSE: GUJTERC. Summary written with AI assistance from the document.
Gujarat Terce Laboratories Ltd: key numbers
- Share price
- ₹39.29
- Market cap
- ₹29.15 Cr
- Revenue (annual)
- ₹47.47 Cr
- Net profit (annual)
- ₹2.20 Cr
- P/E (TTM)
- 14.0×Sector 50.4×
- Promoter holding
- 40.03%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Terce Laboratories Ltd
All →
16:45 IST
BSE
Financial Results
Gujarat Terce Laboratories Q1 FY27 Results: Net Loss of ₹0.2 Cr
Gujarat Terce Laboratories Ltd reported revenue from operations of ₹9 Cr (-17.4% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.2 Cr
22:24 IST
BSE
Financial Results
Gujarat Terce Laboratories Q4 FY26 Results: Turns Profitable, Net Profit ₹0.1 Cr
Gujarat Terce Laboratories Ltd reported revenue from operations of ₹11.4 Cr (-7.3% YoY) and net profit of ₹0.1 Cr for Q4 FY26.
- Key figure
- Net profit ₹0.1 Cr